Drugs that contain Tofacitinib Citrate

1. List of Xeljanz drug patents

XELJANZ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(8 days ago)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Patient Population (NPP) Sep 25, 2023

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's patent expiration?
More Information on Dosage

XELJANZ family patents

3

United States

1

South Africa

1

Denmark

IB

1

IB

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Russia

1

Uruguay

1

Norway

1

Germany

1

Argentina

1

Colombia

1

Brazil

1

Honduras

1

Guatemala

1

Cyprus

1

Spain

1

Peru

1

Korea, Republic of

1

Poland

1

Taiwan, Province of China

1

China

1

Japan

1

Canada

1

Panama

1

New Zealand

1

European Union

2. List of Xeljanz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 25, 2023

Market Authorisation Date: 25 September, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of XELJANZ before it's patent expiration?
More Information on Dosage

3. List of Xeljanz Xr drug patents

XELJANZ XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(8 days ago)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639309 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(10 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(10 years from now)

US11253523 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024

Market Authorisation Date: 23 February, 2016

Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method o...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's patent expiration?
More Information on Dosage

XELJANZ XR family patents

11

United States

6

Korea, Republic of

4

Japan

3

Israel

3

South Africa

3

Australia

3

Russia

3

China

3

Canada

3

New Zealand

3

European Union

2

Denmark

IB

2

IB

2

Mexico

2

Hong Kong

2

Argentina

2

Brazil

2

Singapore

2

Spain

2

Poland

2

Taiwan, Province of China

1

Austria

1

Slovenia

1

Hungary

1

Uruguay

1

Norway

1

Germany

1

Colombia

1

Honduras

1

Portugal

1

Guatemala

1

Cyprus

1

Peru

1

Panama

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in